India's Income Tax Department Tightens Noose Over Sanofi-Aventis' Shantha Biotech Deal; Claim Tax On Deal Made Over An "Indian" Asset
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Sanofi-Aventis is faced with more headwinds in India even as it tries to absorb the negative impact of the recent delisting of Shan 5 - its popular pentavalent vaccine - by the World Health Organization
You may also be interested in...
Sanofi Wins Crucial Tax Case In India Linked To Shantha Deal; Averts Charges Of Up To $170 Million
Sanofi’s deal for India’s Shantha Biotechnics was under the spotlight as India’s Income Tax department alleged that the deal was structured with an intention to avoid taxes. The decision may clear hurdles for other MNCs acquiring Indian companies.
Sanofi Wins Crucial Tax Case In India Linked To Shantha Deal; Averts Charges Of Up To $170 Million
Sanofi’s deal for India’s Shantha Biotechnics was under the spotlight as India’s Income Tax department alleged that the deal was structured with an intention to avoid taxes. The decision may clear hurdles for other MNCs acquiring Indian companies.
Will The Vodafone Win Against India’s Income Tax Department Benefit Sanofi In Shantha Deal?
India Supreme Court ruling in Vodafone case may set precedent for offshore acquisitions, but Sanofi-Shantha deal has key differences.